Latest News and Press Releases
Want to stay updated on the latest news?
-
TEL AVIV, Israel, Aug. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
-
U.S. Investigational Device Exemption (IDE) application submitted to FDA Company to host investor conference call today, August 6, at 8:00am ET TEL AVIV, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) --...
-
TEL AVIV, Israel, July 30, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
-
On-Track to Submit U.S. IDE expected in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR),...
-
TEL AVIV, Israel, May 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
-
TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
-
TEL AVIV, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
-
TEL AVIV, Israel, March 26, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and...
-
TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
-
2018 CGuard™ EPS annual sales increased 55% compared to 2017 On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, Feb. 19, 2019 (GLOBE...